Quality of care delivered to type 2 diabetes mellitus patients in public and private sector facilities in Johannesburg, South Africa by Pinchevsky Y, Raal F, Butkow N, Chirwa T, Distiller L, Rothberg A

Get full text

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data by Sattar, N, Preiss, D, Robinson, J, Djedjos, C, Elliott, M, Somaratne, R, Wasserman, S, Raal, F

Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome by Henry, R, Holman, R, Giugliano, R, Raal, F, Sullivan, D, Honarpour, N, Nelson, P, Elliott, M, Liu, T, Wasserman, S, Somaratne, R, Koren, M